SU MMARY STATEMENT Anthrax toxin is the major cause of death in inhalation of Bacillus anthracis spores. It is composed of three proteins: protective antigen (PA), lethal factor (LF) and edema factor (EF). To express toxicity, PA binds to a cell surface receptor, tumor endothelial marker 8 (TEMS) or capillary morphogenesis gene-2 (CMG2). After proteolytic processing, the oligomerized PA binds to either LF or EF and transports the toxins to endosomes and cytosol. Within the cytosol, EF expresses its adenylyl cyclase activity and LF, a metalloprotease, hydrolyzes members of the mitogen-activated protein kinase (MAPK) kinase family. Therefore, interfering with the toxin functions in the above pathway is an important therapeutic approach. Here we propose a two-prong research. The first is to inactivate and remove LF in the blood plasma during the window of opportunity at an early stage of infection. As a metalloprotease, LF has a narrow substrate specificity and is not inactivated by alpha2-macroglobulin (alpha2M) that are present in the blood at high amounts. We propose to engineer the bait region of alpha2M to gain a new activity for LF inactivation. The new alpha2M may be infused into spore inhalation patients to keep them alive while being treated with antibiotics. The second approach is to interfere with the binding of PA to its cell surface anthrax toxin receptors. We propose to determine the three-dimensional structures of PA-TEM8 and PA-MG2 complexes and use the structural information to design small-molecular inhibitors that interfere with the complex formation. Various milestones are installed in the Research Plan and the final products are planned for human clinical experiments at the end of this program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI062629-05
Application #
7690709
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
5
Fiscal Year
2008
Total Cost
$453,046
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
More, Sunil; Yang, Xiaoyun; Zhu, Zhengyu et al. (2018) Regulation of influenza virus replication by Wnt/?-catenin signaling. PLoS One 13:e0191010
Hu, Zihua; Jiang, Kaiyu; Frank, Mark Barton et al. (2018) Modeling Transcriptional Rewiring in Neutrophils Through the Course of Treated Juvenile Idiopathic Arthritis. Sci Rep 8:7805
Booth, J Leland; Duggan, Elizabeth S; Patel, Vineet I et al. (2018) Gene expression profiling of primary human type I alveolar epithelial cells exposed to Bacillus anthracis spores reveals induction of neutrophil and monocyte chemokines. Microb Pathog 121:9-21
Seshadri, Sudarshan; Pope, Rosemary L; Zenewicz, Lauren A (2018) Glucocorticoids Inhibit Group 3 Innate Lymphocyte IL-22 Production. J Immunol 201:1267-1274
Girton, Alanson W; Popescu, Narcis I; Keshari, Ravi S et al. (2018) Serum Amyloid P and IgG Exhibit Differential Capabilities in the Activation of the Innate Immune System in Response to Bacillus anthracis Peptidoglycan. Infect Immun 86:
Langer, Marybeth; Girton, Alanson W; Popescu, Narcis I et al. (2018) Neither Lys- and DAP-type peptidoglycans stimulate mouse or human innate immune cells via Toll-like receptor 2. PLoS One 13:e0193207
DeVette, Christa I; Andreatta, Massimo; Bardet, Wilfried et al. (2018) NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors. Cancer Immunol Res 6:636-644
Popescu, Narcis I; Silasi, Robert; Keshari, Ravi S et al. (2018) Peptidoglycan induces disseminated intravascular coagulation in baboons through activation of both coagulation pathways. Blood 132:849-860
Fuentes-Mattei, Enrique; Giza, Dana Elena; Shimizu, Masayoshi et al. (2017) Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. EBioMedicine 20:182-192
Dumas, Eric K; Garman, Lori; Cuthbertson, Hannah et al. (2017) Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated. Vaccine 35:3416-3422

Showing the most recent 10 out of 121 publications